1932

Abstract

After a traumatic childhood in Europe during the Second World War, I found that scientific research in Israel was a pleasure beyond my expectations. Over the last 65 year, I have worked on the chemistry and pharmacology of natural products. During the last few decades, most of my research has been on plant cannabinoids, the endogenous cannabinoids arachidonoyl ethanolamide (anandamide) and 2-arachidonoyl glycerol, and endogenous anandamide-like compounds, all of which are involved in a wide spectrum of physiological reactions. Two plant cannabinoids, Δ9-tetrahydrocannabinol and cannabidiol, are approved drugs. However, the endogenous cannabinoids and the anandamide-like constituents have not yet been well investigated in humans. For me, intellectual freedom—the ability to do research based on my own scientific interests—has been the most satisfying part of my working life. Looking back over the 91 years of my long life, I conclude that I have been lucky, very lucky, both personally and scientifically.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-pharmtox-051921-083709
2023-01-20
2024-07-15
Loading full text...

Full text loading...

/deliver/fulltext/pharmtox/63/1/annurev-pharmtox-051921-083709.html?itemId=/content/journals/10.1146/annurev-pharmtox-051921-083709&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Reuter S, Cohen S, Mechoulam R, Kaluszyner A, Tabori AS. 1956. On the mechanisms of DDT resistance. Riv. Parasitol. 17:2125–27
    [Google Scholar]
  2. 2.
    Cohen S, Kaluszyner A, Mechoulam R. 1957. On the fluorination of DDT with HF and HgO. J. Am. Chem. Soc. 79:5979–81
    [Google Scholar]
  3. 3.
    Sondheimer F, Mechoulam R. 1957. Synthesis of steroidal methylene compounds by the Wittig reaction. J. Am. Chem. Soc. 79:5029–33
    [Google Scholar]
  4. 4.
    Pelletier SW, Adityachaudhury N, Tomasz M, Reynolds JJ, Mechoulam R. 1964. Senegenic acid, a pentacyclic nor-triterpene acid. Tetrahedron Lett 5:413065–70
    [Google Scholar]
  5. 5.
    Mechoulam R, Gaoni Y. 1965. The isolation and structure of cannabinolic, cannabidiolic and cannabigerolic acids. Tetrahedron 21:51223–29
    [Google Scholar]
  6. 6.
    Mechoulam R. 1970. Marihuana chemistry. Science 168:39361159–66
    [Google Scholar]
  7. 7.
    Mechoulam R, Shvo J. 1963. The structure of cannabidiol. Tetrahedron 19:122073–78
    [Google Scholar]
  8. 8.
    Gaoni Y, Mechoulam R. 1964. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86:1646–47
    [Google Scholar]
  9. 9.
    Mechoulam R, Shani A, Edery H, Grunfeld Y. 1970. The chemical basis of hashish activity. Science 169:3945611–12
    [Google Scholar]
  10. 10.
    Parker LA, Rock EM, Mechoulam R. 2022. CBD: What Does the Science Say? Cambridge, MA: MIT Press
    [Google Scholar]
  11. 11.
    Kogan N, Rabinowitz R, Levi P, Gibson D, Sandor P et al. 2004. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J. Med. Chem. 47:153800–6
    [Google Scholar]
  12. 12.
    Silva NR, Gomes FV, Fonseca MD, Mechoulam R, Breuer A et al. 2017. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative. Prog. Neuropsychopharmacol. Biol. Psychiatry 79:Pt. B369–77
    [Google Scholar]
  13. 13.
    Alexander SPH. 2016. Therapeutic potential of cannabis-related drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 64:157–66
    [Google Scholar]
  14. 14.
    Kogan NM, Lavi Y, Topping LM, Williams RO, McCann FE et al. 2021. Novel CBG derivatives can reduce inflammation, pain and obesity. Molecules 26:185601–17
    [Google Scholar]
  15. 15.
    Pertwee RG, Rock EM, Guenther K, Limebeer CL, Stevenson LA et al. 2018. Cannabidiolic acid methyl ester, a stable analog of cannabidiolic acid, can produce 5HT1A receptor-mediated suppression of nausea and anxiety in rats. Brit. J. Pharmacol. 175:1100–12
    [Google Scholar]
  16. 16.
    Hen-Shoval D, Amar S, Shbiro L, Smoum R, Haj C et al. 2018. Acute oral cannabidiolic acid methyl ester reduces depression-like behavior in two genetic animal models of depression. Behav. Brain Res. 351:1–3
    [Google Scholar]
  17. 17.
    Zhu YF, Linher-Melville K, Niazmand MJ, Sharma M, Shahid A et al. 2020. An evaluation of the anti-hyperalgesic effects of cannabidiolic acid-methyl ester (CBDA-ME) in a preclinical model of peripheral neuropathic pain. Br. J. Pharmacol. 177:122712–25
    [Google Scholar]
  18. 18.
    Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel G et al. 1980. Chronic administration of CBD to healthy volunteers and epileptic patients. Pharmacology 21:3175–85
    [Google Scholar]
  19. 19.
    Devinsky O, Marsh E, Friedman D, Thiele E, Laux L et al. 2016. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 15:3270–78
    [Google Scholar]
  20. 20.
    Mechoulam R, Lander N, Srebnik M, Breuer A, Segal M et al. 1987. Stereochemical requirements for cannabimimetic activity. Structure-Activity Relationships of the Cannabinoids RS Rapaka, A Makriyannis 15–30 Washington, DC: Natl. Inst. Drug Abuse
    [Google Scholar]
  21. 21.
    Moussaieff A, Shein NA, Tsenter J, Grigoriadis S, Simeonidou C et al. 2008. Incensole acetate: a novel neuroprotective agent isolated from Boswellia carterii. J. Cereb. Blood Flow Metab. 28:71341–52
    [Google Scholar]
  22. 22.
    Moussaieff A, Rimmerman N, Bregman T, Straiker A, Felder CC et al. 2008. Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. FASEB J 22:83024–34
    [Google Scholar]
  23. 23.
    Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. 1988. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:5605–13
    [Google Scholar]
  24. 24.
    Devane WA, Breuer A, Sheskin T, Jarbe TUC, Eisen M et al. 1992. A novel probe for the cannabinoid receptor. J. Med. Chem. 35:112065–69
    [Google Scholar]
  25. 25.
    Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA et al. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:50901946–49
    [Google Scholar]
  26. 26.
    Fride E, Mechoulam R. 1993. Pharmacological activity of the cannabinoid agonist anandamide, a brain constituent. Eur. J. Pharmacol. 231:2313–14
    [Google Scholar]
  27. 27.
    Vogel Z, Barg J, Levy R, Saya D, Heldman E et al. 1993. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61:1352–55
    [Google Scholar]
  28. 28.
    Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE et al. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:183–90
    [Google Scholar]
  29. 29.
    Mechoulam R, Parker L. 2013. The endocannabinoid system and the brain. Annu. Rev. Psychol. 64:21–47
    [Google Scholar]
  30. 30.
    De Melo Reis RA, Isaac AR, Freitas HR, de Almeida MM, Schuck PF et al. 2021. Quality of life and a surveillant endocannabinoid system. Front. Neurosci. 15:747229
    [Google Scholar]
  31. 31.
    Pacher P, Kunos G. 2013. Modulating the endocannabinoid system in human health and disease—successes and failures. FEBS J 280:91918–43
    [Google Scholar]
  32. 32.
    Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH et al. 1998. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353:123–31
    [Google Scholar]
  33. 33.
    Weidenfeld J, Feldman S, Mechoulam R. 1994. The effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 59:2110–12
    [Google Scholar]
  34. 34.
    Fride E, Ginzburg Y, Breuer A, Bisogno T, Di Marzo V et al. 2001. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur. J. Pharmacol. 419:2–3207–14
    [Google Scholar]
  35. 35.
    Hao S, Avraham Y, Mechoulam R, Berry EM. 2000. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur. J. Pharmacol. 392:3147–56
    [Google Scholar]
  36. 36.
    Fride E, Barg J, Levy R, Saya D, Heldman R et al. 1995. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 272:2699–707
    [Google Scholar]
  37. 37.
    Schuel H, Goldstein E, Mechoulam R, Zimmerman AM, Zimmerman S. 1994. Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. PNAS 91:167678–82
    [Google Scholar]
  38. 38.
    Krylatov AV, Uzhachenko RV, Maslov LN, Bernatskaya NA, Makriyannis A et al. 2002. Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: a possible mechanism. Bull. Exp. Biol. Med. 133:2122–24
    [Google Scholar]
  39. 39.
    Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A et al. 2001. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:6855527–31
    [Google Scholar]
  40. 40.
    Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R et al. 2006. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol. Dis. 22:2257–64
    [Google Scholar]
  41. 41.
    Hanus L, Gopher A, Almog S, Mechoulam R. 1993. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36:203032–34
    [Google Scholar]
  42. 42.
    Barg J, Fride E, Hanus L, Levy R, Matus-Leibovitch N et al. 1995. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur. J. Pharmacol. 287:2145–52
    [Google Scholar]
  43. 43.
    Bradshaw HB, Walker JM. 2005. The expanding field of cannabimimetic and related lipid mediators. Br. J. Pharmacol. 144:4459–65
    [Google Scholar]
  44. 44.
    Hanus L, Shohami E, Bab I, Mechoulam R 2014. N-Acyl amino acids and their impact on biological processes. BioFactors 40:4381–88
    [Google Scholar]
  45. 45.
    Arul Prakash S, Kamlekar RK 2021. Function and therapeutic potential of N-acyl amino acids. Chem. Phys. Lipids 239:105114
    [Google Scholar]
  46. 46.
    Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R et al. 2006. N-Arachidonoyl l-serine, a novel endocannabinoid-like brain constituent with vasodilatory properties. PNAS 103:72428–33
    [Google Scholar]
  47. 47.
    Trichopoulou A, Georgiou E, Bassiakos Y, Lipworth L, Lagiou P et al. 1997. Energy intake and monounsaturated fat in relation to bone mineral density among women and men in Greece. Prev. Med. 26:3395–400
    [Google Scholar]
  48. 48.
    Smoum R, Bar A, Tan B, Milman G, Attar-Namdar M et al. 2010. Oleoyl serine, an endogenous regulator of skeletal mass. PNAS 107:4117710–15
    [Google Scholar]
  49. 49.
    Baraghithy S, Smoum R, Drori A, Hadar AR, Gammal AS et al. 2019. Magel2 modulates bone remodeling and mass in Prader-Willi Syndrome by affecting oleoyl serine levels and activity. J. Bone Miner. Res. 34:193–105
    [Google Scholar]
  50. 50.
    Koob GF, Arends MA, Le Moal M 2014. Drugs, Addiction, and the Brain Amsterdam: Elsevier
    [Google Scholar]
  51. 51.
    Naqvi NH, Rudrauf D, Damasio H, Bechara A. 2007. Damage to the insula disrupts addiction to cigarette smoking. Science 315:5811531–34
    [Google Scholar]
  52. 52.
    Naqvi NH, Gaznick N, Tranel D, Bechara A. 2014. The insula: a critical neural substrate for craving and drug seeking under conflict and risk. Ann. N. Y. Acad. Sci. 1316:53–70
    [Google Scholar]
  53. 53.
    Donvito G, Piscitelli F, Muldoon P, Jackson A, Vitale R et al. 2019. N-Oleoyl glycine reduces nicotine reward and withdrawal in mice. Neuropharmacology 148:320–31
    [Google Scholar]
  54. 54.
    Petrie GN, Wills KL, Piscitelli F, Smoum R, Limebeer CL et al. 2019. Oleoyl glycine: interference with the aversive effects of acute naloxone precipitated MWD, but not morphine reward, in male Sprague–Dawley rats. Psychopharmacology 236:92623–33
    [Google Scholar]
  55. 55.
    Ayoub SM, Smoum R, Farag M, Atwal H, Collins SA et al. 2020. Oleoyl alanine (HU595): A stable monomethylated oleoyl glycine interferes with acute naloxone precipitated morphine withdrawal in male rats. Psychopharmacology 237:92753–65
    [Google Scholar]
  56. 56.
    Rock EM, Limebeer CL, Sullivan MT, DeVuono MV, Lichtman AH et al. 2021. N-Oleoylglycine and N-oleoylalanine do not modify tolerance to nociception, hyperthermia, and suppression of activity produced by morphine. Front. Synaptic Neurosci. 13:620145
    [Google Scholar]
  57. 57.
    Monserrat-Martinez A, Gambin Y, Sierecki E. 2019. Thinking outside the bug: molecular targets and strategies to overcome antibiotic resistance. Int. J. Mol. Sci. 20:61255
    [Google Scholar]
  58. 58.
    Feldman M, Smoum R, Mechoulam R, Steinberg D. 2018. Antimicrobial potential of endocannabinoid and endocannabinoid-like compounds against methicillin-resistant Staphylococcus aureus. Sci. Rep. 8:117696
    [Google Scholar]
  59. 59.
    Feldman M, Smoum R, Mechoulam R, Steinberg D. 2020. Potential combinations of endocannabinoid/endocannabinoid-like compounds and antibiotics against methicillin-resistant Staphylococcus aureus. PLOS ONE 15:4e023158
    [Google Scholar]
  60. 60.
    Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R et al. 2010. Cannabinoid receptor dependent and independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor positive and negative prostate cancer cell lines. Carcinogenesis 31:91584–91
    [Google Scholar]
  61. 61.
    Brown I, Wahle KW, Cascio MG, Smoum-Jaouni R, Mechoulam R et al. 2011. Omega-3 N-acylethanolamines are endogenously synthesised from omega-3 fatty acids in different human prostate and breast cancer cell lines. Prostaglandins Leukot. Essent. Fatty Acids 85:6305–10
    [Google Scholar]
  62. 62.
    Redlich C, Dlugos A, Hill MN, Patel S, Korn D et al. 2021. The endocannabinoid system in humans: significant associations between anandamide, brain function during reward feedback and a personality measure of reward dependence. Neuropsychopharmacology 46:51020–27
    [Google Scholar]
  63. 63.
    Pacher P, Kogan NM, Mechoulam R. 2020. Beyond THC and endocannabinoids. Annu. Rev. Pharmacol. Toxicol. 60:637–59
    [Google Scholar]
  64. 64.
    Campos RMP, Aquiar AFL, Paes-Colli Y, Trindade PMP, Fereira BK et al. 2021. Cannabinoid therapeutics in chronic neuropathic pain: from animal research to human treatment. Front. Physiol. 12:785176
    [Google Scholar]
  65. 65.
    Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E et al. 2000. The non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. PNAS 97:9561–66
    [Google Scholar]
  66. 66.
    Kirkland AE, Fadus MC, Gruber SA, Gray KM, Wilens TE et al. 2022. A scoping review of the use of cannabidiol in psychiatric disorders. Psychiatry Res 308:114347
    [Google Scholar]
  67. 67.
    Weiss L, Zeira M, Reich S, Slavin S, Raz I et al. 2008. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 54:244–49
    [Google Scholar]
  68. 68.
    Martínez-Orgado J, Villa M, Del Pozo A. 2021. Cannabidiol for the treatment of neonatal hypoxic-ischemic brain injury. Front. Pharmacol. 11:584533
    [Google Scholar]
  69. 69.
    Giuliano C, Francavilla M, Ongari G, Petese A, Rossini N et al. 2021. Neuroprotective and symptomatic effects of cannabidiol in an animal model of Parkinson's disease. Int. J. Mol. Sci. 22:8920
    [Google Scholar]
  70. 70.
    Cristino L, Bisogno T, Di Marzo V. 2020. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat. Rev. Neurol. 16:19–29
    [Google Scholar]
  71. 71.
    Watt G, Karl T. 2017. In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer's disease. Front. Pharmacol. 8:20
    [Google Scholar]
  72. 72.
    Dudášová A, Keir SD, Parsons ME, Molleman A, Page CP. 2013. The effects of cannabidiol on the antigen-induced contraction of airways smooth muscle in the guinea-pig. Pulm. Pharmacol. Ther. 26:3373–79
    [Google Scholar]
  73. 73.
    O'Reilly EM, Cosgrave JM, Gallagher WM, Perry AS. 2022. Plant-derived cannabinoids as anticancer agents. Trends Cancer 8:5350–57
    [Google Scholar]
/content/journals/10.1146/annurev-pharmtox-051921-083709
Loading
/content/journals/10.1146/annurev-pharmtox-051921-083709
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error